advanced search

Latest Issue

Pulmonary & Nasal Drug Delivery158

Issue No #158 Apr 2024  April 20th, 2024


Download PDF


Inside the magazine

SOFT MIST INHALERS VERSUS NEBULISERS: DELIVERY EQUIVALENCE & FUTURE THERAPIES
EXPERT VIEW
Dr Zaid Aqrawe
Merxin Ltd
SOFT MIST INHALERS VERSUS NEBULISERS: DELIVERY EQUIVALENCE & FUTURE THERAPIES
Zaid Aqrawe, Philippe Rogueda, Darragh Murnane and Bryan Eng, discuss the opportunity presented by soft mist inhalers as an alternative delivery device to nebulisers for inhaled therapies, contrasting the two device categories across multiple factors.
ADDRESSING CNS THERAPIES THROUGH NOSE-TO-BRAIN PATHWAYS
NASAL
Alain Regard
Nemera
ADDRESSING CNS THERAPIES THROUGH NOSE-TO-BRAIN PATHWAYS
Alain Regard, Raphaële Audibert and Audrey Chandra, discuss the advantages of nasal delivery and highlight the challenges of the nose-to-brain pathways.
HUMAN FACTORS IN THE ABSENCE OF A FAMILIAR MENTAL MODEL: CHALLENGES & OPPORTUNITIES IN DRUG SELF-ADMINISTRATION
NASAL
Shai Assia
Clexio Biosciences
HUMAN FACTORS IN THE ABSENCE OF A FAMILIAR MENTAL MODEL: CHALLENGES & OPPORTUNITIES IN DRUG SELF-ADMINISTRATION
Shai Assia explores the intricate challenge of designing drug-device combination products for self-administration by lay users without medical expertise, focusing on targeted nasal drug delivery devices.
Interview: EXPLORING NASAL CASTS IN NASAL DRUG DEVELOPMENT
INTERVIEW
Dr Julie Suman
Aptar Pharma
Interview: EXPLORING NASAL CASTS IN NASAL DRUG DEVELOPMENT
Julie Suman discusses nasal casts, their development, applications and significance for nasal drug product development. 
ADVANCING PHARMACEUTICAL CONTACT APPLICATIONS WITH PEEK: MEETING INCREASING DEMANDS
INDUSTRIALISATION
Marcus Jarman-Smith
Victrex
ADVANCING PHARMACEUTICAL CONTACT APPLICATIONS WITH PEEK: MEETING INCREASING DEMANDS
Marcus Jarman-Smith and Yann Tréguier, discuss the myriad benefits that Victrex’s pharmaceutical-grade PEEK can offer to the drug delivery sector as a material of construction due to its versatile material properties.
HIGH-DOSE DELIVERY PLATFORM FOR CRYSTALLINE DPIs
PULMONARY
Dr Susana Saldanha
Hovione
HIGH-DOSE DELIVERY PLATFORM FOR CRYSTALLINE DPIs
Susana Saldanha, Lídia Santos and Rui Churro, discuss the benefits of crystalline formulations for inhalation devices.
ARCUS<sup>®</sup>: A COMMERCIALISED TECHNOLOGY ENABLING HIGH-DOSE, HIGHLY RESPIRABLE POWDERS
INDUSTRIALISATION
Dr Alan Watts
Catalent
ARCUS®: A COMMERCIALISED TECHNOLOGY ENABLING HIGH-DOSE, HIGHLY RESPIRABLE POWDERS
Alan Watts and Michael Tauber, discuss the requirements and benefits of using spray-dried powders for inhalation, and how ARCUS, used for the successfully commercialised Inbrija® dry powder inhaler, is a prime example of this technology in action.
ADVANCING OINDP CLINICAL TRIALS WITH SPEED AND EFFICIENCY: STRATEGIES FOR SUCCESS
RESPIRATORY
Gemma Budd
Aptar Pharma
ADVANCING OINDP CLINICAL TRIALS WITH SPEED AND EFFICIENCY: STRATEGIES FOR SUCCESS
Gemma Budd and Julie Suman, consider the key issues that preclinical and clinical trials for orally inhaled and nasal drug products must address within the context of the information that regulators are looking for, providing insight, strategies and advice for both novel and generic products in this sector.
BETTER IN VIVO PREDICTION FROM OINDP TESTING: A GOAL WORTH PURSUING?
PULMONARY
Matthew Fenn
Copley Scientific
BETTER IN VIVO PREDICTION FROM OINDP TESTING: A GOAL WORTH PURSUING?
Matthew Fenn and Clair Brooks, consider the motivation for adopting more clinically representative test set-ups in orally inhaled and nasal drug product development and, more specifically, for the demonstration of bioequivalence, as well as the practicalities of doing so and the tools available to support such efforts.
Interview with Sandy Munro, Vectura
INTERVIEW
Dr Sandy Munro
Vectura
Interview with Sandy Munro, Vectura
In this exclusive interview with ONdrugDelivery’s Guy Furness, Sandy Munro, PhD, of Vectura discusses his extensive career, focused on respiratory drug delivery. He shares his insights into current trends within the industry, including the growth of biologics, systemic delivery via inhalation, the potential of mesh nebulisers and connectivity in clinical trials. 
DEEP BREATHS, DEEP DIVES: THE NEW eFLOW INTEGRATED NEBULISER
PULMONARY
Gesa Braunlich
PARI
DEEP BREATHS, DEEP DIVES: THE NEW eFLOW INTEGRATED NEBULISER
Gesa Bräunlich and Michael Hahn discuss PARI’s new eFlow integrated nebuliser.
THE EVOLUTION OF PULMONARY & NASAL DRUG DELIVERY
RESPIRATORY
Mike Needham
Kindeva Drug Delivery
THE EVOLUTION OF PULMONARY & NASAL DRUG DELIVERY
Mike Needham takes a look at the history of, and progress in, inhalation technology and discusses what might lie ahead.
BUBBLE-WRAPPED REMEDIES: HOW LIPID-ENCASED THERAPEUTICS COULD TRANSFORM INHALATION
EXPERT VIEW
Dr Ethan Miller
BUBBLE-WRAPPED REMEDIES: HOW LIPID-ENCASED THERAPEUTICS COULD TRANSFORM INHALATION
Ethan Miller and Heather Jameson shed light on some of the intricacies that lipid-encapsulated therapeutics bring to the realm of inhalation therapies, and some considerations on how the type of inhalation device selected may help to mitigate issues around formulation stability and efficient delivery to target cells.
HOW TO CHOOSE THE RIGHT INTRANASAL VACCINE DEVICE
EXPERT VIEW
Dr Nia Stevens
HOW TO CHOOSE THE RIGHT INTRANASAL VACCINE DEVICE
Nia Stevens, discusses the potential benefits of developing vaccines for intranasal administration with a suitable drug delivery device, as well as the challenges associated with this delivery route.
THE PATH TO NASAL DRUG PRODUCT COMMERCIALISATION
EXPERT VIEW
Eric Kaneps
THE PATH TO NASAL DRUG PRODUCT COMMERCIALISATION
Eric Kaneps discusses the benefits of nasal drug delivery compared with other administration routes – and the challenges in R&D and clinical manufacturing.
EXPLORING THE POTENTIAL OF NEBULISED BIOLOGICS
EXPERT VIEW
Carolina Dantas
EXPLORING THE POTENTIAL OF NEBULISED BIOLOGICS
Carolina Dantas and Ulf Krueger consider the challenges when it comes to the successful delivery of inhaled biological drugs.
Top